바이오인

08:55~09:00

Registration

09:00~09:05

Opening Remarks

Yun Sil Chang, Director of Cell and Gene Therapy Institute, Samsung Medical Center

09:05~09:10

Welcome Address

Kyu-Sung Lee, Director, Research Institute for Future Medicine, Samsung Medical Center

09:10~09:15

Congratulatory Address

Seung Woo park, President of Samsung Medical Center

Session I

Perspective: Advanced Technology of Cell · Gene Therapy to Clinical Progress
Chair : Dong-Ik Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine
         Jeehun Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine

09:15~09:30

Jeehun Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine

TBD

09:30~09:45

Sang Jin Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine

Development of gene therapy for inherited retinal degeneration

09:45~10:00

Byung-Ok Choi, Samsung Medical Center, Sungkyunkwan University School of Medicine

An Open-label, Dose-escalation, Phase 1a Study of Intravenous Injection of allogenic early-passage mesenchymal stem cells (MSCs), derived from Wharton’s Jelly in Patients with Charcot-Marie-Tooth disease type 1A

10:00~10:15

Dongho Choi, College of Medicine, Hanyang University

TBD

10:15~10:30

Discussion

Session II

Translational & Clinical Research of Cell · Gene therapy for Incurable Diseases
Chair : Il-Hoan Oh, The Catholic University of Korea
         Yun Sil Chang, Director of Cell and Gene Therapy Institute, Samsung Medical Center

10:30~11:00

David A. Williams, Harvard Medical School, USA

TBD

11:00~11:05

Discussion

11:05~11:35

Mustafa Sahin, Harvard Medical School, USA

TBD

11:35~11:40

Discussion

11:40~12:10

Anthony E. Oro, Stanford University, USA

TBD

12:10~12:15

Discussion

12:15~13:15

Lunch 

Session III

Perspective: Advanced Technology of Cell Therapy to Clinical Progress
Chair : Ssang-Goo Cho, Konkuk University & StemEXOne Inc.
         Jae Ho Kim, Pusan National University School of Medicine

13:15~13:30

Ji Hyeon Ju, Seoul St. Mary's Hospital, The Catholic Universtiy of Korea

Application of iPS Cell-derived therapeutics for chronic degenerative diseases

13:30~13:45

Yohan Oh, Hanyang University

TBD

13:45~14:00

Kihyun Lee, Ewha Womans University

TBD

14:00~14:15

Discussion

Session IV

Recent Advances and Future Perspectives-Exosome and Organoid
Chair : Seung-Yup Ku, Seoul National University College of Medicine
         Oh Young Bang, Samsung Medical Center, Sungkyunkwan University School of Medicine

14:15~14:30

Jong-Hoon Kim, Korea University

In vitro generation and characterization of vascularized multilineage liver organoids & extracellular vesicles derived from hPSCs

14:30~14:45

Say-June Kim, Seoul St. Mary's hospital, The Catholic Universtiy of Korea

Unlocking Exosome Potential: Innovations for Targetability and Productivity

14:45~15:00

Gi-Hoon Nam, SHIFTBIO INC./Korea University College of Medicine

Cell-Free Nanotherapy Platform Technologies as Revolutionary Regenerative Immunotherapy

15:00~15:15

Jong-Chan Park, Department of Biophysics, Sungkyunkwan University

Functional Brain Organoid-based Future Precision Medicine 

15:15~15:35

Discussion

15:35~15:45

Break

Session V

Advanced disease modeling using Gene-modified cell therapy I
Chair : Joon Ho Wang, Samsung Medical Center, Sungkyunkwan University School of Medicine
         Keon Hee Yoo, Samsung Medical Center, Sungkyunkwan University School of Medicine

15:45~16:00

Yae-Jean Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine

Gene therapy in inborn of immunity (immunodeficiency)

16:00~16:15

Sangsu Bae, Seoul National University College of Medicine

Precise Gene Editing in Rare Diseases

16:15~16:25

Discussion

Session VI

Advanced disease modeling using Gene-modified cell therapy II
Chair : Heechung Kwon, KIRAMS; President, KSGCT; CEO, Gencellmed Inc., Korea
         Hye Ryoun Jang, Samsung Medical Center, Korea

16:25~16:40

Yoon-La Choi, Samsung Medical Center, Sungkyunkwan University School of Medicine

Rewrting the code: advancing therapies for neurofibromatosis and NUT carcinoma. 

16:40~16:55

Yong-Sam Kim, GenKOre

Mutation deletion strategy using TaRGET gene editing platform

16:55~17:10

Jinkuk Kim, Graduate School of Medical Science and Engineering, KAIST

A Framework for Individualized Splice-Switching Oligonucleotide Therapy

17:10~17:25

Discussion

17:25~

Adjourn